Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward
2021; Future Medicine; Volume: 13; Issue: 11 Linguagem: Inglês
10.2217/imt-2021-0054
ISSN1750-7448
AutoresLidia Gatto, Vincenzo Di Nunno, Enrico Franceschi, Alba A. Brandes,
Tópico(s)Immune cells in cancer
ResumoImmunotherapyVol. 13, No. 11 CommentaryChimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forwardLidia Gatto, Vincenzo Di Nunno, Enrico Franceschi & Alba Ariela BrandesLidia Gatto *Author for correspondence: E-mail Address: lidia.gatto83@gmail.comhttps://orcid.org/0000-0001-6300-1244Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy, Vincenzo Di Nunno https://orcid.org/0000-0003-4441-9834Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy, Enrico Franceschi https://orcid.org/0000-0001-9332-4677Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy & Alba Ariela BrandesDepartment of Medical Oncology, Azienda USL of Bologna, Bologna, ItalyPublished Online:3 Jun 2021https://doi.org/10.2217/imt-2021-0054AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: CAR-MCAR-Tglioblastomaimmunotherapytumor-associated macrophagestumor microenvironmentReferences1. Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat. Immunol. 20(9), 1100–1109 (2019).Crossref, Medline, CAS, Google Scholar2. Reardon DA, Brandes AA, Omuro A et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 Phase III randomized clinical trial. JAMA Oncol. 6(7), 1003–1010 (2020).Crossref, Medline, Google Scholar3. Ricklefs FL, Alayo Q, Krenzlin H et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4(3), eaar2766 (2018).Crossref, Medline, Google Scholar4. Adhikaree J, Moreno-Vicente J, Kaur AP, Jackson AM, Patel PM. Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma. Cells 9(2), 263 (2020).Crossref, CAS, Google Scholar5. Kmiecik J, Poli A, Brons NH et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J. Neuroimmunol. 264(1–2), 71–83 (2013).Crossref, Medline, CAS, Google Scholar6. Chongsathidkiet P, Jackson C, Koyama S et al. Author correction: sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 25(3), 529 (2019).Crossref, Medline, CAS, Google Scholar7. Agrawal NS, Miller R Jr, Lal R et al. Current studies of immunotherapy on glioblastoma. J. Neurol. Neurosurg. 1(1), 21000104 (2014).Medline, Google Scholar8. Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22(8), 1865–1874 (2016).Crossref, Medline, CAS, Google Scholar9. Klichinsky M, Ruella M, Shestova O et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38(8), 947–953 (2020).Crossref, Medline, CAS, Google Scholar10. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14(7), 399–416 (2017).Crossref, Medline, CAS, Google Scholar11. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur. J. Cancer 76, 100–109 (2017).Crossref, Medline, CAS, Google Scholar12. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6(6), a021857 (2014).Crossref, Medline, Google Scholar13. Pyonteck SM, Akkari L, Schuhmacher AJ et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19(10), 1264–1272 (2013).Crossref, Medline, CAS, Google Scholar14. Zhu Y, Yang J, Xu D et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68(9), 1653–1666 (2019).Crossref, Medline, CAS, Google Scholar15. Butowski N, Colman H, De Groot JF et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium Phase II study. Neuro-Oncol. 18(4), 557–564 (2016).Crossref, Medline, Google Scholar16. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17(12), 887–904 (2018).Crossref, Medline, CAS, Google Scholar17. Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front. Immunol. 10, 2759 (2019).Crossref, Medline, CAS, Google Scholar18. Chen F, Xu Y, Luo Y et al. Down-regulation of Stat3 decreases invasion activity and induces apoptosis of human glioma cells. J. Mol. Neurosci. 40(3), 353–359 (2010).Crossref, Medline, CAS, Google Scholar19. Gu J, Li G, Sun T et al. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J. Neurooncol. 89(1), 9–17 (2008).Crossref, Medline, CAS, Google Scholar20. Weissenberger J, Priester M, Bernreuther C et al. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin. Cancer Res. 16(23), 5781–5795 (2010).Crossref, Medline, CAS, Google Scholar21. Ott M, Kassab C, Marisetty A et al. Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin. Cancer Res. 26(18), 4983–4994 (2020).Crossref, Medline, CAS, Google Scholar22. Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2(6), 377–391 (2018).Crossref, Medline, CAS, Google Scholar23. Feldman L, Brown C, Badie B. Chimeric antigen receptor T-cell therapy: updates in glioblastoma treatment. Neurosurgery 88(6), 1056–1064 (2021).Crossref, Medline, Google Scholar24. O'Rourke DM, Nasrallah MP, Desai A et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9(399), eaaa0984 (2017).Crossref, Medline, Google Scholar25. Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: lessons learned and road ahead. Immunol. Rev. 290(1), 60–84 (2019).Crossref, Medline, CAS, Google Scholar26. Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81(5), 1201–1208 (2021).Crossref, Medline, CAS, Google Scholar27. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216(1), 15–24 (2008).Crossref, Medline, CAS, Google Scholar28. Koka V, Potti A, Forseen SE et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am. J. Clin. Oncol. 26(4), 332–335 (2003).Crossref, Medline, Google Scholar29. Massari F, Rizzo A, Mollica V, Santoni M. A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?. Future Oncol. 17(15), 1839–1841 (2021).Link, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByHypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini & Alba Ariela Brandes7 June 2022 | Immunotherapy, Vol. 14, No. 10BET inhibitors: the promise of a new generation of immunotherapy in glioblastomaVincenzo Di Nunno, Enrico Franceschi, Lidia Gatto & Alba Ariela Brandes1 December 2021 | Immunotherapy, Vol. 14, No. 3Glioblastoma: Emerging Treatments and Novel Trial Designs26 July 2021 | Cancers, Vol. 13, No. 15 Vol. 13, No. 11 Follow us on social media for the latest updates Metrics Downloaded 352 times History Received 7 March 2020 Accepted 24 May 2021 Published online 3 June 2021 Published in print August 2021 Information© 2021 Future Medicine LtdKeywordsCAR-MCAR-Tglioblastomaimmunotherapytumor-associated macrophagestumor microenvironmentFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)